<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353938</url>
  </required_header>
  <id_info>
    <org_study_id>M-P2</org_study_id>
    <nct_id>NCT00353938</nct_id>
  </id_info>
  <brief_title>Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder</brief_title>
  <official_title>Phase II Pilot Randomized Double-Blind Placebo-Controlled Study of 3,4-methylenedioxymethamphetamine (MDMA)Assisted Psychotherapy in Posttraumatic Stress Disorder (PTSD)- Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Medical Association for Psycholytic Therapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Multidisciplinary Association for Psychedelic Studies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the safety and efficacy of MDMA-assisted psychotherapy in people with
      posttraumatic stress disorder (PTSD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posttraumatic stress disorder (PTSD) occurs after experiencing a traumatic event or events.
      PTSD is a public health problem that causes a great deal of suffering. This study will
      examine whether three six to eight-hour long sessions of methylenedioxymethamphetamine
      (MDMA)-assisted psychotherapy scheduled three to five weeks apart can be safely administered
      to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with
      psychotherapy, when compared with a low (&quot;active placebo&quot;) dose of MDMA, will reduce PTSD
      symptoms, with symptoms measured three times during the study. People who receive the low
      dose of MDMA have the opportunity to take part in a second &quot;open label&quot; study continuation,
      wherein the participant will undergo three MDMA-assisted sessions, with the participant and
      the researchers knowing that a full dose of MDMA is being administered. People who receive
      the full dose of MDMA, and any person who received low-dose MDMA and does not undergo the
      open-label study continuation will have PTSD symptoms measured six and twelve months after
      the third session. People who take part in the open label study continuation have their PTSD
      symptoms checked six and 12 months after the third Phase II MDMA-assisted session.

      MDMA is a substance possessing unique effects that make it well suited to intensive
      psychotherapy. MDMA may belong to a new class of drugs, called entactogens, that produce
      feelings of closeness to others, empathy, well being, and insightfulness. Currently, MDMA is
      scheduled (illegal) in the US and Switzerland and cannot be used outside of research studies
      like this one. Anecdotal reports of therapy conducted before MDMA was made illegal suggest
      that MDMA-assisted psychotherapy may benefit people with PTSD, and there is an ongoing
      placebo-controlled study of MDMA-assisted psychotherapy in people with crime or war-related
      PTSD occurring in the US.

      This study will examine MDMA-assisted psychotherapy in 12 individuals aged 18 years or older
      diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
      Eight of 12 participants will be assigned to receive the full dose of MDMA, and four will be
      assigned to receive a low or &quot;active placebo&quot; dose of MDMA during each of three experimental
      sessions. People will be assigned to full or low-dose MDMA &quot;by chance,&quot; as by flipping a
      coin.

      The study will last approximately four and a half months. In addition, people assigned to
      receive full-dose MDMA will have their PTSD symptoms measured six and 12 months later. The
      study involves up to eleven ordinary psychotherapy visits, without any MDMA, and three low or
      full-dose MDMA-assisted sessions. One psychotherapy session is scheduled 24 hours after each
      MDMA-assisted session.

      PTSD symptoms will be measured at the start of the study, three weeks after the second of
      three low or full-dose MDMA sessions, three weeks after the third low or full-dose MDMA
      session (approximately six weeks after the second session), two months after the third
      experimental session, and six and 12 months after either the third experimental session, or,
      if enrolled in Phase II, six and 12 months after the third open-label MDMA-assisted therapy
      session. Participants will undergo EEG (measuring brain waves) in combination with ERP
      (evoked response potential) technique before and after MDMA-assisted therapy that aim at
      spotting specific changes in brain function and structure that might be related to problems
      with early information processing, for which people with PTSD are known to have difficulties.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale (CAPS</measure>
    <time_frame>baseline, three weeks post-experimental session 2, three weeks post-experimental session 3, two, six and 12 months post-experimental session 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Diagnostic Scale (PDS)</measure>
    <time_frame>- baseline, three weeks post experimental session 2, three weeks post-experimental session 3, 2, 6 and 12 months post-experimental session 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactions to Research Participation Questionnaire (RRPQ) - 12 months post-experimental session 3; in Phase II participants, 12 months post-MDMA session 3</measure>
    <time_frame>2 months post-experimental session 3; in Phase II participants, 12 months post-MDMA session 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Units of Distress (SUD)</measure>
    <time_frame>During each of three experimental sessions, and, if applicable, during each of three Phase II MDMA-assisted session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG and ERP with acoustic startle -</measure>
    <time_frame>baseline, three weeks post experimental session 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>3,4-methylenedioxymethamphetamine 125 mg &amp; Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,4-methylenedioxymethamphetamine 125 and 62.5 m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3,4-methyelendioxymethamphetamine 25 mg &amp; Psychotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3,4-methylenedioxymethamphetamine 25 and 12.5 mg MDMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-methylenedioxymethamphetamine 125 mg</intervention_name>
    <description>Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2-2.5 hours later they receive 62.5 mg MDMA orally.</description>
    <arm_group_label>3,4-methylenedioxymethamphetamine 125 mg &amp; Psychotherapy</arm_group_label>
    <other_name>MDMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-methyelendioxymethamphetamine 25 mg</intervention_name>
    <description>Participants will receive a 25 mg MDMA and if investigator and participant agree, 2 to 2.5 hours later a dose of 12.5 mg MDMA.</description>
    <arm_group_label>3,4-methyelendioxymethamphetamine 25 mg &amp; Psychotherapy</arm_group_label>
    <other_name>MDMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>Psychotherapy performed by a team of two co-therapists</description>
    <arm_group_label>3,4-methylenedioxymethamphetamine 125 mg &amp; Psychotherapy</arm_group_label>
    <arm_group_label>3,4-methyelendioxymethamphetamine 25 mg &amp; Psychotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with posttraumatic stress disorder (PTSD).

          -  PTSD still remains after one or more prior treatment, with treatment including
             psychotherapy (talk therapy) or drug therapy

          -  May meet criteria for a mood disorder

          -  Must be at least 18 years old

          -  Must be able to stop taking psychiatric medication during the course of the study,
             from the start of the study to the follow-up two months after experimental session 3.

          -  Must agree to follow all rules and instructions relating to the experimental session,
             including restrictions on food and substance (alcohol and drug) consumption.

          -  Must be willing to stay overnight at the researcher's office after each experimental
             session until the non-drug session occurring the next morning.

          -  Must be willing to be contacted by one of the researchers on a daily basis for a week
             after each experimental session.

          -  Female participants of childbearing potential must have a negative pregnancy test and
             must agree to use an effective form of birth control.

          -  Participants must have sufficient proficiency in speaking the German language to
             participate in MDMA-assisted psychotherapy. Participants must be able to read
             documents in German.

        Exclusion Criteria:

          -  Cannot have history of or current primary psychotic disorder or bipolar affective
             disorder-1.

          -  Dissociative identity disorder, or an eating disorder with active purging or
             borderline personality disorder.

          -  Evidence or history of significant hematological, endocrine, cerebrovascular,
             cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or
             neurological disease, including seizure disorder. (People with hypothyroidism who are
             on adequate and stable thyroid replacement will not be excluded).

          -  Uncontrolled hypertension, peripheral vascular disease, hepatic disease (with or
             without abnormal liver enzymes), or history of hyponatremia or hyperthermia.

          -  Being pregnant or lactating (nursing), or not practicing an effective method of birth
             control.

          -  Weight of less than 50 or more than 105 kg.

          -  Patients reporting prior use of &quot;Ecstasy&quot; more than 5 times or at any time within the
             previous 6 months.

          -  People who would present a serious suicide risk or who are likely to require
             hospitalization during the course of the study.

          -  People who need ongoing concomitant therapy with a psychotropic drug.

          -  Meeting DSM-IV criteria for substance abuse or dependence for any substance save
             caffeine or nicotine in the past 60 days.

          -  People who cannot give adequate consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Oehen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>private practice, Biberist, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Offices of Peter Oehen MD</name>
      <address>
        <city>Biberist</city>
        <state>Solothurn</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (Â± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013 Jan;27(1):40-52. doi: 10.1177/0269881112464827. Epub 2012 Oct 31.</citation>
    <PMID>23118021</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2006</study_first_submitted>
  <study_first_submitted_qc>July 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2006</study_first_posted>
  <disposition_first_submitted>July 31, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 5, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 15, 2011</disposition_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD, MDMA, psychotherapy, Switzerland</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

